Advanced Oncotherapy PLC
LSE:AVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Advanced Oncotherapy PLC
Total Liabilities & Equity
Advanced Oncotherapy PLC
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Advanced Oncotherapy PLC
LSE:AVO
|
Total Liabilities & Equity
£153.2m
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
33%
|
|
|
Smith & Nephew PLC
LSE:SN
|
Total Liabilities & Equity
$10.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Total Liabilities & Equity
$2.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
24%
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Total Liabilities & Equity
£81.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Total Liabilities & Equity
£65m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Inspiration Healthcare Group PLC
LSE:IHC
|
Total Liabilities & Equity
£36.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
22%
|
|
Advanced Oncotherapy PLC
Glance View
Advanced Oncotherapy Plc engages in the development of proton therapy systems. The firm is focused on developing and supplying technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to the patient's healthy tissues. The linear design of LIGHT allows for an active longitudinal modulation along the proton beam axis, and the variation of the proton beam by electronic means during cancer treatment. The feature of LIGHT offers hospitals and treatment centers the flexibility to customize cancer treatment plans based on a range of energies. This could provide an alternative to passive modulation, that degrades the beam along its path, causing it to lose integrity. In addition, a dynamic transversal modulation allows a precise three dimensional (3D) treatment of the tumors via the spot scanning technique.
See Also
What is Advanced Oncotherapy PLC's Total Liabilities & Equity?
Total Liabilities & Equity
153.2m
GBP
Based on the financial report for Jun 30, 2022, Advanced Oncotherapy PLC's Total Liabilities & Equity amounts to 153.2m GBP.
What is Advanced Oncotherapy PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
33%
Over the last year, the Total Liabilities & Equity growth was 21%. The average annual Total Liabilities & Equity growth rates for Advanced Oncotherapy PLC have been 24% over the past three years , 29% over the past five years , and 33% over the past ten years .
